Primary systemic therapy (PST) of locally advanced breast cancer using Doxorubicin/Docetaxel combination.
BACKGROUND
PST of locally advanced breast carcinomas causes tumour shrinkage and down-staging, therefore, optimal circumstances for surgery.


METHODS
We treated 25 stage IIIA-IIIB breast cancer patients with PST (Doxorubicin/Docetaxel). Histological diagnosis (core biopsy) was available in each case. Tumour regression and cardiac function were recorded regularly.


RESULTS
Five patients showed complete pathological remission. Instead of 19 mastectomies, only nine were performed and 16 patients underwent breast-conserving therapy.


CONCLUSIONS
Using PST breast conservation rate is improved.
Dank
M
M
Department of Diagnostic, Radiology and Oncotherapy, Semmelweis University, Ulloi ut 78a, 1082 Budapest, Hungary. dank@radi.sote.hu
Zergenyi
E
E
Domotori
Z S
ZS
Lahm
E
E
Kulka
J
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D043823:Taxoids
D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D017239:Paclitaxel